Korro Bio (FREQ) Stock Forecast, Price Target & Predictions
FREQ Stock Forecast
Korro Bio stock forecast is as follows: an average price target of $7.00 (represents a 2236.45% upside from FREQ’s last price of $0.30) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
FREQ Price Target
The average price target for Korro Bio (FREQ) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 2236.45% upside from FREQ's last price of $0.30.
FREQ Analyst Ratings
According to 2 Wall Street analysts, Korro Bio's rating consensus is 'Buy'. The analyst rating breakdown for FREQ stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Korro Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | Chardan Capital | $7.00 | $2.04 | 243.14% | 2236.45% |
The latest Korro Bio stock forecast, released on Dec 08, 2022 by Chardan Capital company, set a price target of $7.00, which represents a 243.14% increase from the stock price at the time of the forecast ($2.04), and a 2236.45% increase from FREQ last price ($0.30).
Korro Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.30 | $0.30 | $0.30 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Korro Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Korro Bio's last price of $0.30. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 14, 2023 | Cowen & Co. | - | Outperform | Initialise |
| Dec 08, 2022 | Chardan Capital | - | Buy | Initialise |
Korro Bio's last stock rating was published by Cowen & Co. on Feb 14, 2023. The company Initialise its FREQ rating from "null" to "Outperform".
Korro Bio Financial Forecast
Korro Bio Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $-28.11M | - | $9.42M | $4.65M | $9.95M | $11.25M | $8.52M | $7.26M | $4.71M | $24.24M |
| Avg Forecast | - | - | - | - | - | $15.19M | $6.27M | $31.00M | $16.25M | $16.25M | $6.71M | $3.70M | $14.46M | $14.46M | $8.07M | $7.72M | $22.46M | $22.46M |
| High Forecast | - | - | - | - | - | $18.23M | $7.53M | $25.87M | $13.56M | $19.50M | $5.60M | $3.09M | $12.07M | $17.35M | $6.74M | $6.44M | $18.74M | $26.95M |
| Low Forecast | - | - | - | - | - | $12.15M | $5.02M | $36.13M | $18.94M | $13.00M | $7.82M | $4.31M | $16.85M | $11.57M | $9.41M | $9.00M | $26.17M | $17.96M |
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | -1.73% | - | 1.40% | 1.26% | 0.69% | 0.78% | 1.06% | 0.94% | 0.21% | 1.08% |
Korro Bio's average Quarter revenue forecast for Mar 22 based on 10 analysts is $31.00M, with a low forecast of $36.13M, and a high forecast of $25.87M. FREQ's average Quarter revenue forecast represents a -210.29% decrease compared to the company's last Quarter revenue of $-28.11M (Dec 21).
Korro Bio EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| EBITDA | - | - | - | - | $-12.66M | $-18.62M | $-20.39M | $-22.47M | $63.24M | $-24.23M | $-16.54M | $-19.77M | $-9.87M | $-5.03M | $-5.77M | $-4.66M | $-5.27M | $-361.00K |
| Avg Forecast | - | - | - | - | - | $-16.29M | $-15.16M | $-21.04M | $-1.52M | $-17.42M | $-16.22M | $-14.69M | $-1.35M | $-6.46M | $-5.45M | $-4.93M | $-2.09M | $-334.45K |
| High Forecast | - | - | - | - | - | $-13.03M | $-12.13M | $-16.84M | $-1.26M | $-13.94M | $-12.97M | $-11.75M | $-1.13M | $-5.17M | $-4.36M | $-3.95M | $-1.75M | $-267.56K |
| Low Forecast | - | - | - | - | - | $-19.55M | $-18.20M | $-25.25M | $-1.77M | $-20.91M | $-19.46M | $-17.63M | $-1.57M | $-7.75M | $-6.54M | $-5.92M | $-2.44M | $-401.35K |
| Surprise % | - | - | - | - | - | 1.14% | 1.34% | 1.07% | -41.73% | 1.39% | 1.02% | 1.35% | 7.32% | 0.78% | 1.06% | 0.94% | 2.52% | 1.08% |
10 analysts predict FREQ's average Quarter EBITDA for Mar 22 to be $-21.04M, with a high of $-16.84M and a low of $-25.25M. This is -133.28% lower than Korro Bio's previous annual EBITDA (Dec 21) of $63.24M.
Korro Bio Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| Net Income | - | - | - | - | $-11.61M | $-19.55M | $-21.29M | $-23.39M | $63.10M | $-25.16M | $-17.66M | $-20.38M | $-10.23M | $-5.34M | $-6.03M | $-4.91M | $-5.49M | $-575.00K |
| Avg Forecast | $56.91M | $49.57M | $58.21M | $-10.71M | $-12.18M | $-16.92M | $-16.18M | $-21.90M | $-20.31M | $-18.09M | $-17.31M | $-15.14M | $-11.82M | $-6.87M | $-5.69M | $-5.20M | $25.11M | $-532.72K |
| High Forecast | $45.14M | $39.32M | $46.16M | $-8.49M | $-12.18M | $-13.53M | $-12.95M | $-17.52M | $-16.11M | $-14.48M | $-13.85M | $-12.11M | $-9.37M | $-5.49M | $-4.55M | $-4.16M | $19.91M | $-426.18K |
| Low Forecast | $68.69M | $59.83M | $70.25M | $-12.92M | $-14.03M | $-20.30M | $-19.42M | $-26.28M | $-24.51M | $-21.71M | $-20.77M | $-18.17M | $-14.26M | $-8.24M | $-6.83M | $-6.24M | $30.30M | $-639.26K |
| Surprise % | - | - | - | - | 0.95% | 1.16% | 1.32% | 1.07% | -3.11% | 1.39% | 1.02% | 1.35% | 0.87% | 0.78% | 1.06% | 0.94% | -0.22% | 1.08% |
Korro Bio's average Quarter net income forecast for Mar 22 is $-21.90M, with a range of $-26.28M to $-17.52M. FREQ's average Quarter net income forecast represents a -134.71% decrease compared to the company's last Quarter net income of $63.10M (Dec 21).
Korro Bio SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| SG&A | - | - | - | - | $10.11M | $8.56M | $8.00M | $9.48M | $-28.53M | $9.33M | $9.50M | $9.74M | $9.16M | $6.51M | $5.96M | $6.25M | $5.00M | $20.27M |
| Avg Forecast | - | - | - | - | - | $6.27M | $5.94M | $8.88M | $15.38M | $6.71M | $6.35M | $3.50M | $13.69M | $8.37M | $5.63M | $6.62M | $21.26M | $18.78M |
| High Forecast | - | - | - | - | - | $7.53M | $7.13M | $10.65M | $12.84M | $8.05M | $5.30M | $2.92M | $11.42M | $10.05M | $6.75M | $7.94M | $17.74M | $22.53M |
| Low Forecast | - | - | - | - | - | $5.02M | $4.75M | $7.10M | $17.93M | $5.37M | $7.40M | $4.08M | $15.95M | $6.70M | $4.50M | $5.29M | $24.78M | $15.02M |
| Surprise % | - | - | - | - | - | 1.36% | 1.35% | 1.07% | -1.85% | 1.39% | 1.50% | 2.78% | 0.67% | 0.78% | 1.06% | 0.94% | 0.24% | 1.08% |
Korro Bio's average Quarter SG&A projection for Dec 23 is -, based on 9 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to FREQ last annual SG&A of $10.11M (Sep 23).
Korro Bio EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| EPS | - | - | - | - | $-0.31 | $-0.55 | $-0.61 | $-0.67 | $1.82 | $-0.73 | $-0.52 | $-0.60 | $-0.30 | $-0.16 | $-0.19 | $-0.16 | $-0.19 | $-0.02 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.29 | $-0.33 | $-0.61 | $-0.69 | $-0.66 | $-0.55 | $1.25 | $-0.51 | $-0.27 | $-0.32 | $-0.36 | $-0.22 | $-0.25 | $0.68 | $-0.63 |
| High Forecast | $1.22 | $1.06 | $1.25 | $-0.23 | $-0.33 | $-0.48 | $-0.55 | $-0.52 | $-0.44 | $0.99 | $-0.40 | $-0.21 | $-0.25 | $-0.29 | $-0.17 | $-0.20 | $0.54 | $-0.50 |
| Low Forecast | $1.86 | $1.62 | $1.90 | $-0.35 | $-0.38 | $-0.74 | $-0.83 | $-0.80 | $-0.66 | $1.50 | $-0.62 | $-0.33 | $-0.39 | $-0.43 | $-0.27 | $-0.30 | $0.82 | $-0.76 |
| Surprise % | - | - | - | - | 0.94% | 0.90% | 0.88% | 1.02% | -3.31% | -0.59% | 1.02% | 2.22% | 0.94% | 0.44% | 0.86% | 0.64% | -0.28% | 0.03% |
According to 10 Wall Street analysts, Korro Bio's projected average Quarter EPS for Mar 22 is $-0.66, with a low estimate of $-0.80 and a high estimate of $-0.52. This represents a -136.26% decrease compared to FREQ previous annual EPS of $1.82 (Dec 21).
Korro Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.56 | $17.50 | 3025.00% | Buy |
| FREQ | Korro Bio | $0.30 | $7.00 | 2233.33% | Buy |
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| ONCT | Oncternal Therapeutics | $3.98 | $28.00 | 603.52% | Buy |
| PRTG | Portage Biotech | $2.97 | $19.50 | 556.57% | Buy |
| SRRK | Scholar Rock | $8.03 | $29.50 | 267.37% | Buy |
| STTK | Shattuck Labs | $3.50 | $12.00 | 242.86% | Buy |
| OLMA | Olema Pharmaceuticals | $11.83 | $27.00 | 128.23% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| PRLD | Prelude Therapeutics | $4.85 | $8.75 | 80.41% | Sell |
| ELYM | Eliem Therapeutics | $7.39 | $13.00 | 75.91% | Buy |
| ABSI | Absci | $4.02 | $6.00 | 49.25% | Buy |
| ADVM | Adverum Bio | $6.76 | $7.00 | 3.55% | Buy |
FREQ Forecast FAQ
Is Korro Bio a good buy?
Yes, according to 2 Wall Street analysts, Korro Bio (FREQ) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of FREQ's total ratings.
What is FREQ's price target?
Korro Bio (FREQ) average price target is $7 with a range of $7 to $7, implying a 2236.45% from its last price of $0.3. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Korro Bio stock go up soon?
According to Wall Street analysts' prediction for FREQ stock, the company can go up by 2236.45% (from the last price of $0.3 to the average price target of $7), up by 2236.45% based on the highest stock price target, and up by 2236.45% based on the lowest stock price target.
Can Korro Bio stock reach $0?
FREQ's average twelve months analyst stock price target of $7 supports the claim that Korro Bio can reach $0 in the near future.
What are Korro Bio's analysts' financial forecasts?
FREQ's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-22.892M (high $-20.676M, low $-26.953M), average SG&A $0 (high $0, low $0), and average EPS is $-0.62 (high $-0.56, low $-0.73).
Did the FREQ's actual financial results beat the analysts' financial forecasts?
Based on Korro Bio's last annual report (Dec 2021), the company's revenue was $14.05M, which missed the average analysts forecast of $42.91M by -67.25%. Apple's EBITDA was $-81.125M, beating the average prediction of $-49.85M by 62.74%. The company's net income was $-84.686M, beating the average estimation of $-70.849M by 19.53%. Apple's SG&A was $37.18M, beating the average forecast of $31.95M by 16.37%. Lastly, the company's EPS was $-2.47, beating the average prediction of $-0.0847 by 2816.52%. In terms of the last quarterly report (Dec 2021), Korro Bio's revenue was $-28.108M, missing the average analysts' forecast of $16.25M by -272.97%. The company's EBITDA was $63.24M, missing the average prediction of $-1.516M by -4272.89%. Korro Bio's net income was $63.1M, missing the average estimation of $-20.307M by -410.73%. The company's SG&A was $-28.534M, missing the average forecast of $15.38M by -285.49%. Lastly, the company's EPS was $1.82, missing the average prediction of $-0.55 by -430.91%